This article explores why most smokers haven’t embraced reduced-risk products, revealing how current vape and heated tobacco tech fails to deliver the ritual, satisfaction, and simplicity smokers still seek.
This article explores why most smokers haven’t embraced reduced-risk products, revealing how current vape and heated tobacco tech fails to deliver the ritual, satisfaction, and simplicity smokers still seek.
This whitepaper presents the findings of our systematic review conducted with Inter Scientific, evaluating the most efficacious interventions in the complex landscape of tobacco harm reduction.
With urgent and important demand for LFTs, jeopardizing performance, ease-of-use, supply chain availability, and low cost isn’t an option – but sustainability strategies are evolving in response to consumer expectations.
Ice cream and blood are two things you probably don’t want to think about simultaneously, but how a substance flows is a vitally important consideration for many products.
The ENDS Adoption Journey outlines seven steps a smoker must take to substitute combustible tobacco products with ENDS.
What should we make of the Medicines and Healthcare products Regulatory Agency (MHRA) updating its guidance for licensing e-cigarettes as medicinal products?
It can be extremely challenging to identify an optimum business and product strategy in the current cannabinoid market.
We were asked to resolve the difficult engineering and manufacturing issues that were jeopardising this novel inhaler’s launch. Our team identified and resolved the problems, validated the design and production tooling so Voke could gain CE approval and enter volume manufacture.
The impact of the pandemic has dramatically shaken up the world of conferences and events. Ana Romero, Digital Marketer and Events Coordinator at Cambridge Design Partnership, looks back over a tumultuous year and asks, “what next”? [CDP team at Pharmapack in Paris, February 2020. Left to right; Jon Powell, Senior Consultant,…
The 2016 National Health Interview Survey of 17,000 Americans reports that 1 in 5 people suffer chronic pain1. Significant effort and money are being invested by companies ranging from large Pharma to small Tech start-ups to address this “pain epidemic” as evidenced in the clinicaltrials.gov database showing over 2,500 “pain”…